Výsledky vyhledávání - Adi Turjeman
- Zobrazuji výsledky 1 - 6 z 6
-
1
-
2
-
3
The beneficial effects of sodium-glucose cotransporter 2 inhibitors on anemia in type 2 diabetes-a real world study Autor Tali Steinmetz, Shira Goldman, Kim Ben Tikva Kagan, Dana Bielopolski, Shira Buchrits, Amir Schechter, Shiri Kushnir, Adi Turjeman, Timna Agur, Alon Grossman, Anat Gafter Gvili, Benaya Rozen Zvi
Vydáno 2025Artigo -
4
Duration of antibiotic treatment for Gram-negative bacteremia – Systematic review and individual participant data (IPD) meta-analysis Autor Adi Turjeman, Elodie von Dach, José Molina, Erica Franceschini, Fidi Koppel, Dana Yelin, Yael Dishon‐Benattar, Cristina Mussini, Jesús Rodríguez‐Baño, José Miguel Cisneros, Angela Huttner, Mical Paul, Leonard Leibovici, Dafna Yahav
Vydáno 2022Artigo -
5
Effect of 5-Day Nitrofurantoin vs Single-Dose Fosfomycin on Clinical Resolution of Uncomplicated Lower Urinary Tract Infection in Women Autor Angela Huttner, Anna Kowalczyk, Adi Turjeman, Tanya Babich, Caroline Brossier, Noa Eliakim‐Raz, Katarzyna Kosiek, Begoña Martínez de Tejada, Xavier Roux, Shachaf Shiber, Ursula Theuretzbacher, Elodie von Dach, Dafna Yahav, Leonard Leibovici, Maciek Godycki-Ćwirko, Johan W. Mouton, Stephan Harbarth
Vydáno 2018Artigo -
6
Seven Versus 14 Days of Antibiotic Therapy for Uncomplicated Gram-negative Bacteremia: A Noninferiority Randomized Controlled Trial Autor Dafna Yahav, Erica Franceschini, Fidi Koppel, Adi Turjeman, Tanya Babich, Roni Bitterman, Ami Neuberger, Nesrin Ghanem‐Zoubi, Antonella Santoro, Noa Eliakim‐Raz, Barak Pertzov, Tali Steinmetz, Anat Stern, Yaakov Dickstein, Elias Maroun, Hiba Zayyad, Jihad Bishara, Danny Alon, Yonatan Edel, Elad Goldberg, Claudia Venturelli, Cristina Mussini, Leonard Leibovici, Mical Paul
Vydáno 2018Artigo
Vyhledávací nástroje:
Související témata
Internal medicine
Medicine
Randomized controlled trial
Adverse effect
Antibiotics
Biology
Confidence interval
Microbiology
Bacteremia
Cochrane Library
Diabetes mellitus
Endocrinology
Meta-analysis
Surgery
Type 2 diabetes
Urinary system
Agonist
Anemia
Ciprofloxacin
Clinical endpoint
Clinical trial
Discontinuation
Dysuria
Fosfomycin
Gastroenterology
Glucagon-like peptide 1 receptor
Glucagon-like peptide-1
Hazard ratio
Incidence (geometry)
Interquartile range